Acesion Pharma is a technology company.
Pioneering better treatments for atrial fibrillation.
Acesion Pharma has raised $51.0M across 2 funding rounds.
Acesion Pharma has raised $51.0M in total across 2 funding rounds.
The premise of your query is incorrect: Acesion Pharma is not a technology company—it is a biotech/pharmaceutical company developing drug therapies for cardiac arrhythmia.
Acesion Pharma is a Danish biotech company pioneering first-in-class drug treatments for atrial fibrillation (AF), the most common type of cardiac arrhythmia.[1][3] Founded in 2011 as a spin-off from Neurosearch and the University of Copenhagen, the company develops small-molecule drugs that inhibit SK ion channels—a novel therapeutic approach designed to be more effective and safer than existing treatments.[3][4]
The company addresses a significant unmet medical need. Existing AF therapies have limited efficacy and carry serious risks of adverse events, including life-threatening ventricular arrhythmias.[6] With an estimated 2.7 to 6.1 million people in the US alone currently affected by AF—expected to grow to 25 million across the EU and US by 2030—Acesion targets a large and expanding patient population.[2][3]
Acesion Pharma was founded in 2011 based on research initiated in 2008 at the University of Copenhagen, combined with chemistry expertise from Neurosearch.[4] The company emerged from academic research into SK channel inhibition as a novel mechanism for treating cardiac arrhythmias. This scientific foundation distinguishes Acesion's approach from conventional AF treatments, which typically rely on electrical cardioversion or drugs with limited efficacy.
The company has progressed through multiple funding rounds, raising $59.5 million in total funding, including a $47 million Series B round.[5] By 2018, Acesion had advanced to clinical-stage development, receiving regulatory approval to commence its first Phase I study for its lead compound AP30663.[6]
Acesion operates within the cardiovascular drug development sector, addressing a condition that receives comparatively less biotech attention despite its prevalence and clinical burden.[2] The company's focus on AF reflects a broader trend toward precision medicine and mechanism-based drug discovery, moving away from broad-spectrum treatments toward targeted ion channel modulation.
The timing is favorable: an aging global population is driving AF incidence upward, while existing treatment options remain inadequate. Acesion's approach capitalizes on advances in structural biology and ion channel pharmacology that have made selective SK inhibition feasible.
Acesion Pharma represents a focused, science-driven approach to solving a major unmet need in cardiology. The company's progression from preclinical studies to Phase I clinical trials demonstrates meaningful advancement, though the path to market approval remains lengthy and uncertain, as with all drug development programs.
The company's future hinges on clinical trial success, regulatory approval timelines, and competitive dynamics with other AF therapies in development. If Acesion's SK channel inhibitors demonstrate superior efficacy and safety in human trials, the company could establish a significant market position in a large and growing patient population. The broader trend toward personalized, mechanism-based cardiovascular therapies works in Acesion's favor, positioning it as a potential innovator in an underserved therapeutic area.
Acesion Pharma has raised $51.0M in total across 2 funding rounds.
Acesion Pharma's investors include Canaan Partners, Hatteras Venture Partners, OrbiMed, Broadview Ventures.
Acesion Pharma has raised $51.0M across 2 funding rounds. Most recently, it raised $48.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $48.0M Series B | Canaan Partners, Hatteras Venture Partners, OrbiMed | |
| Dec 1, 2014 | $3.0M Venture Round | Broadview Ventures |